INTEGRITISSUE — Programmable Biology for Off-Earth Survival

Human biology was selected for one gravity, a 24-hour day, a magnetosphere that filters most of the cosmic-ray spectrum, a co-evolved microbiome, populations measured in millions, and a lifespan whose evolutionary anchor is fertility-and-grandchildren rather than career radiation budgets. Mars violates almost every one of those assumptions, and a multi-year stay in interplanetary space pushes career radiation limits past their design margins under any honest accounting. The biology question for off-Earth survival splits cleanly into three. The first is radiation: how human bodies tolerate the high-Z high-energy ion flux of galactic cosmic rays, the burst doses of solar particle events, and the secondary fragmentation that thin shielding produces. The second is microgravity: how bone, muscle, vestibular, cardiovascular, and ocular systems behave under chronic 0.38 g (Mars) or 1/6 g (Moon) or microgravity (transit) over years. The third is the meta-biology question: how cellular health, immune competence, microbiome stability, and aging trajectories are maintained over the long durations that the first two questions assume. INTEGRITISSUE treats them as one program because the failure modes interact, but the analysis here keeps them separate, because the literature has frequently conflated them and the conflation has produced confused arguments on all sides.

The three questions are different

The phrase “off-Earth medicine” gets used to mean at least three distinct things, and the conflation has cost the field a decade of clarity. The first is the radiation-resilience claim: that human cells, tissues, and bodies can be engineered or pharmacologically protected to tolerate the chronic galactic-cosmic-ray exposure of a multi-year Mars mission, plus the burst-dose solar-particle-event exposure that current shielding cannot fully eliminate, without exceeding the career stochastic-cancer-risk thresholds that the radiation-protection literature has converged on. The second is the microgravity-countermeasure claim: that the muscular, skeletal, cardiovascular, vestibular, and visual losses that astronauts exhibit in microgravity can be prevented or reversed by a combination of resistive exercise, pharmacological intervention, and (where the evidence supports it) genetic modification. The third is the aging-and-chronic-stress claim: that the chronic stressors of off-Earth life (radiation, microgravity, isolation, altered microbiome, altered photoperiod, altered nutrition) accelerate biological aging in measurable ways, and that biological-aging interventions — partial epigenetic reprogramming, senolytics, mitochondrial transfer — are part of the off-Earth-medicine toolkit rather than separable from it.

The three claims are independent. A program can succeed at radiation resilience and fail at the microgravity-countermeasure question; a program can solve both and fail at the aging trajectory; a program can solve aging at the cellular level and find that the system-level integration produces emergent failure modes that none of the component characterizations predict. The relevant question for INTEGRITISSUE is not which of the three is hardest. The relevant question is how to engineer all three simultaneously, with the constraint that the failure modes of each compound rather than cancel.

The most-cited starting point for the off-Earth medicine conversation is the radiation-protection literature, and the most-cited author within it is Marco Durante (GSI Helmholtz Center, Darmstadt) — whose decade-long body of work, summarized in his Life Sciences in Space Research survey “Space radiation protection: Destination Mars,” has framed the field’s consensus position.¹ Durante’s headline statement — “as it stands today, we can’t go to Mars due to radiation; it would be impossible to meet acceptable dose limits” — is the load-bearing diagnosis around which the rest of INTEGRITISSUE is organized. The 2022 NASA NCRP-recommended career dose limit for astronauts is 600 mSv (effective dose) regardless of age and sex, replacing the previous gender- and age-stratified system; a Mars round-trip mission delivers approximately 1 Sv of dose-equivalent under typical solar conditions, with substantial variability depending on the trajectory and the solar cycle phase. The mission, on current shielding, is at or above the career limit. The ESA Trace Gas Orbiter measurements have shown that just the six-month outbound journey produces approximately 60% of the career dose limit. Closing that gap is what the radiation-resilience leg of INTEGRITISSUE is for.

The mass-and-physiology economics of off-Earth medicine

Before the molecular biology, the systems-level economics. The Mars-class mission delivers a clinical-care environment that has no resupply, no full-spectrum medical specialty consult, no MRI, limited surgical capability, and population sizes measured in single digits to low dozens. The on-board medical kit must be miniaturized, shelf-stable for years, and capable of being administered by crew with cross-trained-not-specialist medical training under microgravity-and-radiation conditions where many drug-class effects deviate measurably from Earth-clinical baselines.² The research program for INTEGRITISSUE has to take this clinical-environment constraint seriously. It is not enough to identify a radiation-resilience mechanism in a Petri dish; the mechanism has to be deliverable, monitorable, and recoverable-from-failure in a context where the nearest backup is on Earth and approximately 30 light-minutes away under best-case-orbit conditions.

The clinical-care literature on Mars-class missions has converged on a small number of design-discipline propositions. Pharmaceutical shelf-life is the largest single mass-budget driver in the on-board medical kit, and many drug classes (particularly biologics) degrade significantly over multi-year storage even under refrigeration. The on-board drug formulary has to be biased toward small molecules, freeze-stable formulations, and on-demand-synthesis routes (e.g., bioreactor-based recombinant production of biologics from frozen iPSC banks). The diagnostic workflow has to bias toward tests that are biomarker-and-blood-based rather than imaging-and-histology-based, with the exception of point-of-care ultrasound, which has been validated as a multi-purpose imaging modality in resource-constrained terrestrial settings and on the ISS. The surgical workflow has to be designed around what crew can actually perform under microgravity conditions — primarily wound management, percutaneous procedures, and limited laparoscopy — with autonomous robotic surgical capability under research investment but not yet at flight readiness.

The systems-level question is what the on-board capability mix looks like. The INTEGRITISSUE program treats this as the integrated-clinical-architecture question, with cell-therapy, gene-therapy, and bedside-bioprinting capabilities composing into the on-board capability mix in an explicit cost-and-mass-budget analysis. The capability mix is not the same as the Earth-clinical mix; it is biased toward modalities that can be delivered with frozen iPSC banks plus on-demand differentiation, and biased away from modalities that require continual cold-chain biologics resupply.

What INTEGRITISSUE is, technically

Three streams of contemporary biology converge to make INTEGRITISSUE tractable. None of them is the answer alone. The integration of several into a habitat-scale clinical architecture is the open frontier, and it is what the INTEGRITISSUE research program pursues.

Gene editing and the precision-pharmacology frontier

The CRISPR/Cas9 toolkit, awarded the Nobel Prize in Chemistry in 2020, gave the field programmable DNA cleavage. Base editing — the 2016 Nature paper by Komor, Kim, Packer, Zuris, and Liu — gave programmable single-base substitutions without double-strand breaks, dramatically reducing the off-target risk that has been the regulatory barrier to first-generation CRISPR therapeutics.³ Prime editing — the 2019 Nature paper by Anzalone, Randolph, Davis, and Liu — gave programmable multi-base substitutions, including small insertions and deletions, again without double-strand breaks.⁴ The combined toolkit, in 2025, supports targeted modification of essentially any genomic locus at therapeutic-grade specificity.

The regulatory translation has been remarkably rapid. The FDA approval of Casgevy (exa-cel) in December 2023 — the first CRISPR-edited cellular therapy approved in any jurisdiction — and Lyfgenia in the same month, both for sickle cell disease, opened the regulatory pathway for gene-edited therapies. As of late 2025, more than nineteen base- and prime-editing clinical trials are underway, with seven having reported clinical outcomes. Prime Medicine’s PM359 — the first individualized prime-edited therapy in a clinical trial — restored 58–66% NADPH oxidase function in a patient with chronic granulomatous disease in May 2025, demonstrating the platform’s applicability to extremely rare diseases for which classical drug development is uneconomic. The regulatory and clinical infrastructure for INTEGRITISSUE-class interventions is not speculative; it is operational, with first-generation products on the market and a robust pipeline behind them.

For INTEGRITISSUE the relevance is direct: the gene-editing toolkit is the molecular machinery by which radiation-resilience, microgravity-countermeasure, and aging-trajectory interventions are delivered. The translational pathway from “lab demonstrates Dsup-mediated radioprotection in human HEK293 cells” to “FDA-cleared therapy that delivers Dsup transiently to astronaut tissues for the duration of a Mars transit” passes through the same regulatory framework that Casgevy cleared. The framework is not yet sufficient — chronic, periodic, multi-mechanism interventions for asymptomatic-population radiation prophylaxis are not currently licensable — but the regulatory architecture exists.

Stem cell biology and induced pluripotency

The 2006 Cell paper by Takahashi and Yamanaka, demonstrating that four transcription factors (Oct4, Sox2, Klf4, c-Myc — the “Yamanaka factors”) can revert adult cells to pluripotent stem cells, is the foundational result of the modern cell-therapy era and earned Yamanaka the 2012 Nobel Prize in Physiology or Medicine.⁵ The platform has matured through twenty years of clinical translation. The 2025 Vertex VX-880 (zimislecel) results — a stem-cell-derived, fully-differentiated islet-cell therapy for type 1 diabetes — are the most-cited current example, with 12 of 12 evaluable patients in the Phase 1/2 trial demonstrating engraftment and islet function and 10 of 12 (83%) achieving insulin independence at the 365-day follow-up endpoint, published in the New England Journal of Medicine in 2025.⁶ Cardiac, retinal, and hepatic organoid platforms are at preclinical to early-clinical maturity; the next-generation Vertex program (VX-264, an islet-encapsulation device for non-immunosuppressed delivery) is in clinical trials.

For INTEGRITISSUE, the iPSC platform is the substrate for two distinct off-Earth medicine capabilities. First, autologous frozen iPSC banks provide a multi-year-shelf-stable source from which differentiated tissues can be generated on demand: replacement islets, retinal cells, cardiomyocytes, hepatocytes. Second, the same iPSC banks provide the substrate for partial reprogramming interventions (described below) that can be administered without the immune-rejection risk of allogeneic therapies. The on-board iPSC bank is the most-leveraged single asset in the INTEGRITISSUE clinical architecture; the cost-and-mass budget of the bank is the binding constraint on what cellular-therapy capabilities the on-board clinic can support.

Comparative biology of long-lived and stress-resistant organisms

The third stream is comparative biology. Tardigrades, naked mole rats, elephants, bowhead whales, bristlecone pines, and bdelloid rotifers have evolved DNA-repair, anti-cancer, and stress-tolerance mechanisms vastly more capable than humans’. Each of these systems is a candidate for transfer into human cells. The mechanisms are characterized at varying depth; the engineering question is how to combine them safely at the cell-line and organism levels.

The headline result is the tardigrade Damage Suppressor (Dsup) protein from Ramazzottius varieornatus, identified by Hashimoto, Horikawa, Saito and colleagues in their 2016 Nature Communications paper.⁷ Dsup binds nucleosomes and physically protects chromatin from hydroxyl-radical-mediated DNA breaks. Transfected human HEK293 cells show approximately 40% suppression of X-ray-induced DNA fragmentation and substantially improved survival under acute radiation. The mechanism is unique to tardigrades and unrelated to any natural human DNA-repair pathway — Dsup is, on this view, a transferable evolutionary innovation that human cells would benefit from acquiring. Recent NIH work (Byrne lab, 2024) demonstrated mRNA-LNP delivery of Dsup into mouse oral and rectal tissue, with measurable radioprotection of healthy tissue against radiation therapy — a near-term clinical translation pathway through radiation oncology that doubles as a space-medicine pathway.

The complementary mechanism is the elephant TP53 dosage finding. African elephants carry approximately 20 copies of the TP53 tumor-suppressor gene compared to one copy in humans, plus approximately 19 retroduplicated TP53RTG genes producing a hyperactive DNA-damage response — the result of an evolutionary trajectory in which large-bodied mammals required cancer-resistance mechanisms beyond what the human background level provides.⁸ The 2016 eLife paper by Sulak, Fong, Mar and colleagues characterized the mechanism; subsequent work has shown that the elephant TP53 dosage favors apoptosis of damaged cells over DNA repair (the “kill the bad cells before they become cancers” strategy). Mouse “super-p53” transgenics (with one or two extra TP53 copies) show enhanced tumor suppression with otherwise normal aging — a key safety datum for human application.

The third major mechanism is from naked mole rats. The Gorbunova / Seluanov lab at the University of Rochester has spent two decades characterizing naked mole rat longevity and cancer resistance. Their 2025 Science paper identified four amino-acid substitutions in the naked mole rat cGAS protein (the cytosolic DNA sensor that triggers the cGAS-STING innate immune pathway) that reduce ubiquitination and degradation of cGAS, allowing nuclear cGAS to promote rather than suppress homologous-recombination DNA repair via FANCI/RAD50. The translational pathway is direct: replace four residues in human cGAS via base or prime editing.

Other characterized mechanisms include high-molecular-weight hyaluronan synthase from naked mole rats (the HAS2-NMR variant produces unusually long-chain hyaluronic acid, the apparent mechanical basis of naked mole rat cancer resistance), Cladosporium melanin radiosynthesis (the “Chernobyl reactor fungus” mechanism, theoretically transferable but undemonstrated at mammalian-organism scale), and Deinococcus radiodurans DNA-repair systems (which support survival of acute doses of 10 kGy or more, far above the human lethal range). The frontier is combinatorial: engineering human cell lines that combine Dsup + elephant-style TP53 dosage + NMR cGAS variants + HMW-hyaluronan synthase + melanin biosynthetic operons, then characterizing the dose-response surfaces across the NASA Galactic Cosmic Ray Simulator at Brookhaven National Laboratory. No consortium currently runs combinatorial trials at this scale because each lab focuses on one mechanism. This is the single highest-leverage gap in the field, and it is the principal target of INT-A, the radiation-resilience strand of the program.

Partial epigenetic reprogramming

Aging is not a single process. It is the convergence of multiple molecular failures: DNA damage accumulation, mitochondrial dysfunction, proteostasis loss, stem cell exhaustion, telomere attrition, cellular senescence, and — critically — epigenetic drift. The pattern of methylation marks on DNA, which controls which genes are expressed in which cell types, gradually loses fidelity with age, producing the cellular-identity confusion and tissue-function decline that characterizes biological aging. Yamanaka’s original 2006 finding established that the four-factor reprogramming completely resets cell identity to pluripotency.⁵ Juan Carlos Izpisúa Belmonte, then at Salk and now Senior Vice President at Altos Labs, demonstrated in 2016 that partial reprogramming — cyclic or transient OSKM expression — rejuvenates cells without erasing their identity. This is the foundation for the modern reprogramming-as-rejuvenation field.

The seminal translational result came from David Sinclair’s lab at Harvard. The 2020 Nature paper by Lu, Brommer, Tian and colleagues demonstrated that AAV delivery of just three factors (OSK, dropping the oncogenic c-Myc) into retinal ganglion cells reversed age-related vision loss and restored youthful DNA-methylation patterns in aged mice and in glaucoma models.⁹ The result is the most cited piece of evidence for the rejuvenation-via-partial-reprogramming hypothesis. Life Biosciences received FDA clearance in late 2025 for ER-100, the first human cellular-reprogramming clinical trial, targeting open-angle glaucoma and non-arteritic ischemic optic neuropathy. Altos Labs (initial funding of approximately $3 billion from Yuri Milner and Jeff Bezos) has organized a substantial fraction of the partial-reprogramming research community. The September 2024 Science Translational Medicine paper from Belmonte’s group at Altos demonstrated lifespan extension and healthspan gains in mice, with elevated tumorigenesis risk that has become the safety-critical-path question for human translation.

The space-medicine application is direct. Chronic radiation, microgravity, and isolation impose accelerated biological aging on astronauts. Partial reprogramming is the candidate intervention to reverse this damage at the cellular level, periodically through a long mission, before the cumulative damage produces irreversible tissue dysfunction. The measurement infrastructure for any of this work comes from Vadim Gladyshev’s lab at Brigham and Women’s / Harvard Medical School. Gladyshev has produced the next generation of biological-age clocks — DamAge and AdaptAge, causality-enriched clocks that distinguish detrimental from adaptive methylation changes by Mendelian-randomization-based identification of causal CpG sites; scAge, a single-cell epigenetic-age clock; and OmicAge, a plasma-proteome-based organ-specific aging model — all published in Nature Aging and related journals between 2023 and 2024.¹⁰ Without these tools, no aging or stress-recovery intervention can be evaluated rigorously, because the conventional Horvath-class clocks measure correlative methylation patterns rather than causal aging trajectories.

Radiation hardening — the central sub-problem

Galactic cosmic rays (GCRs) are the single hardest spaceflight hazard to mitigate. Unlike solar particle events, which can be passively shielded with mass and timed against the solar cycle, GCRs include high-Z high-energy ions whose dense ionization tracks produce a unique biological damage signature, including hippocampal and dendritic alterations seen in rodent models at mission-relevant doses. Thin shielding can worsen GCR exposure due to secondary fragmentation: incoming heavy ions interact with shielding atoms to produce showers of lighter, faster particles that can carry more total ionization than the original primary. The shielding mass required to substantially reduce GCR dose is on the order of metres of water-equivalent, which is operationally infeasible for mass-budget reasons on any near-term mission. The biological hardening pathway is, on this view, not a complement to shielding; it is the primary intervention.

Five biological strategies are under active research, and the frontier — addressed by INT-A — is combining them. The first is the tardigrade Dsup mechanism described above.⁷ The second is the elephant TP53 dosage strategy described above.⁸ The third is the naked mole rat cGAS variant described above. The fourth is melanin-based radiosynthesis, the Cladosporium sphaerospermum mechanism in which the fungus generates ATP from ionizing radiation via melanized pigmentation; this is theoretically transferable but undemonstrated at mammalian-organism scale, and Lisa Nip’s MIT Media Lab work has been the most public articulation of the engineering pathway. The fifth is Deinococcus radiodurans-derived DNA-repair systems, particularly the suite of proteins that support survival of acute radiation doses far above the human lethal range; these are theoretically transferable but at very early stage.

The combinatorial cell-line work — engineering human iPSCs with Dsup, elephant TP53 dosage, NMR cGAS, HMW-hyaluronan synthase, and melanin biosynthetic operons in a single line, then characterizing the dose-response surfaces across acute and chronic radiation exposures — is the central INT-A activity. The Brookhaven NASA Galactic Cosmic Ray Simulator is the facility at which the dose-response work is conducted; the simulator produces ion-spectra approximating the GCR field, and the dose-and-tissue characterization at the simulator is the empirical anchor for the engineered-cell-line program. The combinatorial work has not been done because no single laboratory has both the mechanism portfolio and the simulator access required; the INT-A consortium structure is designed to bridge that gap.

Bone, muscle, and the microgravity problem

Astronauts on the International Space Station lose 1–1.5% of bone mineral density per month and significant muscle mass, particularly in the antigravity musculature, even with aggressive resistive exercise on the ARED (Advanced Resistive Exercise Device). Mars at 0.38 g is intermediate between Earth and microgravity, but the long-duration biological effects at intermediate gravity are unknown and not assessable from ISS data alone — the ISS data set is microgravity, the Earth data set is one g, and the intermediate point has not been characterized in any large-mammal model.

The most promising biological countermeasure is myostatin and activin pathway inhibition. NASA’s Rodent Research-19 (“Mighty Mice in Space”), led by Se-Jin Lee at the University of Connecticut and Emily Germain-Lee at Connecticut Children’s Medical Center, launched mice to the ISS with the soluble ACVR2B/Fc decoy that binds both myostatin and activin A. The flown mice showed muscle mass and bone density comparable to ground controls — a complete preservation of microgravity-induced losses — published in PNAS in 2020.¹¹ Smith and colleagues showed similar results with the YN41 myostatin antibody. Multiple human myostatin-pathway inhibitors are in clinical trials: LY2495655 (Eli Lilly), bimagrumab (Novartis), and others. None has yet shown sufficient functional benefit in elderly populations to clear FDA approval for sarcopenia, but the mechanism is validated. The sclerostin-pathway inhibitor romosozumab (Evenity, approved for osteoporosis) provides a complementary lever specifically for bone density, with established clinical efficacy.

The space-medicine application is straightforward: Mars-bound crews receive a long-acting myostatin/activin inhibitor plus a sclerostin-pathway modulator on launch, preserving musculoskeletal function through transit and surface stay. The clinical-evidence base supports the intervention; the regulatory framework for asymptomatic-prophylactic use is not yet in place for either drug class. INT-B, the microgravity-countermeasure strand of the program, focuses on the regulatory and clinical-trial work required to bring these interventions to flight readiness, in parallel with the basic-science work on intermediate-gravity (lunar / Mars) biology that no current programme is funded to pursue at scale.

Tissue replacement and ultra-safe cell lines

Some space-medicine problems require not gene editing but tissue replacement. Radiation-induced cancers need surgical resection and reconstruction. Trauma in habitats far from hospitals needs in-situ tissue regeneration. Long-duration aging requires periodic organ refresh. The current state of the art is rich at the component-tissue level — iPSC-derived islet cells (Vertex zimislecel, clinically validated for type 1 diabetes⁶); cardiac organoids (Charles Murry, Christine Mummery, Gordana Vunjak-Novakovic labs, with first-in-human trials approaching); retinal organoids (the Yoshiki Sasai legacy continued by Botond Roska and others, with multiple Phase 1/2 trials); hepatic organoids (Hans Clevers, Meritxell Huch labs, preclinical) — but the off-Earth-medicine question is how to maintain an autologous iPSC bank, transport it on a Mars transit, and bedside-bioprint replacement tissue when needed. No national programme is funded specifically for the integrated answer. This is a gap INT-C is built to fill.

The complementary frontier is ultra-safe cell lines. George Church (Harvard / Wyss Institute) and Jef Boeke (NYU Langone) lead the GP-write consortium’s Ultra-Safe Cells effort, the goal of which is to recode all 64 standard genetic codons to a reduced (e.g. 57- or 61-codon) set, removing redundant codons across the entire genome. The consequences of successful recoding are profound: complete viral resistance (viruses cannot replicate in cells whose codon usage their genomes do not match), incorporation of non-canonical amino acids, and a clean-slate biological substrate that can be engineered in ways that natural cells cannot be. E. coli has been recoded with 321 instances of a single codon removed, the seminal 2013 Science paper by Lajoie and colleagues.¹² Recoding the human genome would require approximately 400,000 edits across 20,000 genes — a 10-year-frontier challenge that depends on continued advances in synthesis and editing throughput. Status: theoretically sound, undemonstrated at mammalian-genome scale.

The off-Earth-medicine relevance of ultra-safe cell lines is twofold. First, viral pandemics are existential threats to small isolated populations, and the off-Earth habitat has minimal natural-immunity buffer. Second, the engineered-microbiome, engineered-tissue-regeneration, and synthetic-biology platforms that the program depends on can be substantially safer in ultra-safe-cell-line variants. Both rationales are speculative at the deployment timeline; INT-C funds the basic work as a long-arc research bet rather than a near-term deployment program.

Definitional bounds

Before moving to the failure-mode and integration questions, four exclusions are worth being explicit about, because the loose use of “longevity,” “transhumanism,” and “post-human biology” in the discourse has produced confusions that make the substantive arguments harder to have.

INTEGRITISSUE does not mean consciousness upload, memory transfer, or post-biological substrates. The program is somatic-and-cellular biology, not computational neuroscience or speculative substrate-independence. The biology question for off-Earth survival is durable enough biology, not biology-replaced-by-computation. The two are not the same project, and the conflation has produced both bad science fiction and bad research-program design.

INTEGRITISSUE does not mean single-gene IQ enhancement, designer babies, or germline modification at scale. The program focuses on somatic and ex-vivo iPSC routes for the simple reason that germline modification raises ethical, regulatory, and biosecurity concerns that are not addressable by the engineering work alone. The germline question — whether and how to apply any of these technologies heritably — is flagged as a separate, deeply ethically contested question outside near-term scope. The 2018 He Jiankui CCR5-edited-twins event is the canonical cautionary tale; the field’s regulatory and ethical infrastructure is not currently in a state where germline INTEGRITISSUE-class interventions could be conducted responsibly, and the program does not pursue them.

INTEGRITISSUE does not mean pharmacology replaces shielding, exercise, or environmental engineering. The program is biological intervention as a complement to, not a substitute for, the standard ECLSS and operational countermeasures: shielded habitat structures during solar particle events, regular resistive exercise, vitamin and mineral supplementation, structured photoperiods, microbiome-stabilization protocols. The biological-intervention layer is the most-leveraged additional capability when the standard countermeasures have hit their physical limits, but it is not a replacement for them.

INTEGRITISSUE does not mean aging is solved. The program targets cellular-and-tissue interventions that improve healthspan at the time horizons relevant to off-Earth missions (years to decades). It does not target lifespan extension beyond the natural human range, it does not promise indefinite postponement of mortality, and it treats the stronger longevity claims with the skepticism the evidence warrants. The 2024 Belmonte Science Translational Medicine paper showed lifespan extension in genetically-accelerated-aging mouse models with elevated tumorigenesis risk; the translation to non-accelerated wild-type mice, let alone humans, is a multi-decade research arc with substantial uncertainty about both magnitude and safety. INTEGRITISSUE is honest about this rather than the alternative.

These exclusions are not throat-clearing. They are the load-bearing definitional choices that determine what the rest of the analysis is about, and they constrain what the program is allowed to claim.

The historical lineage

Off-Earth medicine is not a new field. The cumulative body of operational-and-research evidence spans approximately seventy years and is the substrate from which the program builds. Three lineages matter for the current architecture.

The first is the operational space-medicine record. The U.S. and Soviet/Russian space programs have, between them, accumulated approximately fifty thousand person-days of human spaceflight medical data, primarily on the ISS over the 2000s and 2010s. The data set is the empirical base for the microgravity-countermeasure literature; the bone-density-loss rates, the muscle-loss patterns, the vestibular and ocular changes (including the Spaceflight-Associated Neuro-ocular Syndrome characterized in the 2010s), the cardiovascular deconditioning, and the immune-system perturbations are documented with high statistical power for microgravity exposures up to approximately one year. The 2015–2016 Scott Kelly / Mikhail Korniyenko one-year mission and the comparative twin study with Mark Kelly produced the most-cited single body of long-duration human-spaceflight data; the NASA Twins Study published in Science in 2019 and subsequent papers documented the methylation, telomere, immune, and cognitive changes observed.

The second lineage is the radiation-protection literature, anchored by the work of Marco Durante (GSI Darmstadt), Francis Cucinotta (formerly NASA, now University of Nevada Las Vegas), and the international ICRP (International Commission on Radiological Protection) framework.¹ The career-dose limits and the risk-coefficient framework that NASA and ESA operate under are derived from the Hiroshima/Nagasaki atomic-bomb survivor cohort follow-up, the radiation-therapy patient cohort, and (increasingly) animal-model studies of high-Z high-energy ion exposure. The honest summary of the radiation-protection literature is that the dose-response curves at Mars-mission-relevant low-dose-rate exposures are not yet well-characterized, that the linear-no-threshold extrapolation that the regulatory framework uses is contested at the low-dose end, and that the biological mitigation pathway — the INT-A research focus — is the most-leveraged way to reduce the residual risk that physical shielding cannot eliminate.

The third lineage is the modern molecular biology of stress and aging, anchored by the Yamanaka iPSC discovery (2006), the Liu base-editing and prime-editing platforms (2016, 2019), the Hashimoto Dsup discovery (2016), the Sulak elephant TP53 finding (2016), the Sinclair/Lu OSK retinal-rejuvenation result (2020), the Reiter/Vorholt synthetic methylotrophy work (2024, relevant via the gut-microbiome-engineering pathway), and the Gladyshev causality-enriched-clock framework (2024).^34578910 These are the molecular tools and the measurement infrastructure that the program builds on. The lineage is recent — most of the load-bearing results post-date 2010 — and the pace of progress has been accelerating.

Three risk scenarios

Honest planning for the program requires honest enumeration of the failure modes. We name three. They are not exhaustive. They are the ones the design has to take seriously.

Scenario A — Tumorigenesis from chronic interventions

The first failure mode is the tumorigenesis scenario. Several of the candidate INTEGRITISSUE interventions — partial reprogramming, elephant-TP53 dosage modification, naked-mole-rat cGAS substitution — modify the cellular damage-response and identity-control machinery in ways that, at the wrong dose, produce neoplastic transformation. The 2024 Belmonte Science Translational Medicine paper documented elevated tumor incidence in mice receiving partial reprogramming over extended durations. The risk is real and measurable. The mitigation is the combination of conservative dosing, rigorous biomarker-based monitoring (using the Gladyshev causality-enriched clocks and complementary tumorigenesis markers¹⁰), and the kind of long-duration safety data that requires multi-year primate and early-human studies before any flight deployment.

The implication for the program is that the timeline for INT-aging interventions is necessarily longer than the timeline for INT-radiation interventions. Radiation-resilience interventions have analogous mechanisms (radioprotection in radiation-oncology contexts) with shorter clinical-trial timelines; aging interventions are intrinsically long-duration and the safety bar is correspondingly higher. The program treats this as a sequencing constraint rather than as a reason to abandon the work.

Scenario B — Microbiome and immune dysregulation

The second failure mode is the microbiome-and-immune scenario. Off-Earth populations carry a small subset of the Earth-evolved microbiome, in habitats whose surfaces and atmospheres have selected microbial ecosystems that are radically different from Earth-evolved ones. The ISS surface microbiome data (the Microbial Tracking Mission and successors) document this directly: ISS surfaces accumulate microbial communities dominated by Staphylococcus and Cladosporium, with low diversity and selection for antibiotic-resistant strains. The crew gut microbiome shifts measurably over months. The immune system in microgravity exhibits both reduced T-cell function (latent-virus reactivation: VZV, EBV, CMV are documented in ISS crews) and shifted innate-immune balance.

The risk is that an off-Earth crew, exposed simultaneously to chronic radiation, microgravity, altered microbiome, and INTEGRITISSUE-class interventions, exhibits emergent immune-system failure modes that none of the component characterizations predict. The mitigation is microbiome-engineering protocols (engineered probiotic strains delivering specific metabolites, gut-axis stabilization, periodic Earth-baseline microbial reintroduction from frozen banks), supplemented by aggressive monitoring and conservative-dose pharmacological intervention. INT-D, the integration strand of the program, focuses on the microbiome-immune-pharmacology integration as a single problem rather than three separate problems.

Scenario C — Successful staged deployment

The third scenario, which we treat as the base case if the engineering and clinical work are competent, is staged deployment in which radiation-resilience cell-line modifications are validated through radiation-oncology applications on Earth before any flight deployment, microgravity-countermeasure pharmacology is validated through sarcopenia and osteoporosis indications on Earth before flight deployment, partial-reprogramming interventions are validated through specific Earth-clinical indications (glaucoma, NAION, geriatric frailty) before flight deployment, and the integrated clinical architecture is validated at lunar-base scale before Mars deployment. Each stage validates the assumptions of the next. The process is multi-decade and not glamorous. It is also the only process that has any track record of working.

The base-case deployment, on this view, is not a Mars-direct INTEGRITISSUE megaproject. It is a sequence of Earth-clinical, then lunar-validation, then Mars-deployment validations, with the Earth-clinical applications providing both the scientific evidence base and the regulatory pathway that the off-Earth applications inherit. This sequencing is, again, a feature rather than a bug; the Earth-clinical applications carry their own commercial and humanitarian rationale, and the off-Earth applications are the natural endpoint of a research program whose intermediate steps are valuable on their own terms.

What technical work bears on this

The reason INTEGRITISSUE appears on a research-company website at all, rather than in a journal of biomedicine, is that the technical work is coupled to the rest of the civilizational stack in ways that are not always obvious. We pull three threads back from the biology question to the broader technical agenda.

The first is that INTEGRITISSUE depends on ENERA for the medical, scientific, and life-support power loads that any clinically-active habitat needs to run. The on-board iPSC-bank cryogenic storage, the bedside-bioprinting capability, the autonomous diagnostic-and-therapeutic infrastructure, the bioreactor-based on-demand recombinant biologics production — each is a non-trivial power load, and the integrated clinical architecture’s power budget is one of the binding constraints on what capabilities the on-board clinic can support.

The second is that INTEGRITISSUE feeds into ARCANE through microbiome engineering and personalized nutrition. Engineered probiotic strains delivering Dsup, ACE2 modulators, or specific metabolites in vivo are simultaneously food and medicine; the engineered-microbiome surface is the integration point between the food-production infrastructure and the medical-intervention infrastructure, and the program treats it as such rather than as separate domains.

The third is that the long-duration human-health and oversight protocols that the program produces become design inputs to AI Safety and Cognitive Computing. Chronic neurocognitive monitoring of crews, drug-effect evaluation under microgravity, and astronaut-AI interaction patterns under stress and isolation are all biology-medicine-AI hybrid questions that no single field is funded to address comprehensively. The bedside-bioprinting and iPSC infrastructure couples directly to Humanoid Robotics for autonomous medical manipulation in remote habitats, and the autonomous-clinical-decision-support pipelines couple to Agentic Systems.

The summary is this. A civilization that has solved the energy problem and the food problem but cannot keep its inhabitants biologically intact across multi-year off-Earth deployments is a civilization that is not actually capable of living off-Earth. INTEGRITISSUE is the biological-resilience layer of the civilization-stack architecture. It is the layer that determines whether durable human presence beyond Earth is a possibility or a survival-curve-truncated experiment. The program treats it as the former, while being explicit about the work and time required to make the proposition real.

Open questions in the field

The research-program agenda. We name nine. These are the questions the program is funded to address.

1. Combinatorial radiation-resilience characterization across multiple mechanisms, dose levels, and tissue types — the dose-response surfaces no single lab is currently producing, addressed at the NASA Galactic Cosmic Ray Simulator at Brookhaven.
2. In-vivo gene-therapy delivery improvements — next-generation lipid nanoparticles and AAVs that survive long-duration storage, deliver effectively in microgravity-altered tissues, and tolerate the immunological perturbations of off-Earth physiology.
3. Long-duration safety of partial reprogramming, particularly tumorigenesis risk under chronic cyclic OSK exposure, building on the 2024 Belmonte-lab safety findings.
4. Microbiome engineering for closed-loop habitats — gut-axis interventions for radiation resilience, immune stability, and engineered-probiotic delivery of therapeutic metabolites.
5. Bedside organoid culture and autonomous bioprinting in resource-constrained habitats, building on the Vertex VX-880 and academic-organoid platforms.⁶
6. Synthetic chromosomes and ultra-safe cell lines at scale, building on the Lajoie codon-recoded E. coli and the GP-write consortium.¹²
7. Intermediate-gravity biology at lunar (1/6 g) and Mars (0.38 g) levels, where the existing data set is essentially zero and where the long-duration physiology is not assessable from ISS microgravity data alone.
8. Causality-enriched biological-aging measurement at off-Earth crew scale, building on the Gladyshev DamAge / AdaptAge / OmicAge framework.¹⁰
9. Integrated clinical-architecture mass-and-power optimization — what capability mix the on-board clinic supports under realistic Mars-mission constraints.

Each of these is a multi-year research effort. None of them is solved. All of them are tractable. The INTEGRITISSUE program funds work on each, in collaboration with the laboratories named above and with the open scientific community that is the natural home of this work.

Connections

INTEGRITISSUE depends on ENERA for the medical, scientific, and life-support power loads any clinically-active habitat needs to run. It feeds into ARCANE through microbiome engineering — engineered probiotic strains delivering Dsup, ACE2 modulators, or specific metabolites in vivo are simultaneously food and medicine. On the AI side, the long-duration human-health and oversight protocols this program produces become design inputs to AI Safety and Cognitive Computing — chronic neurocognitive monitoring, drug-effect evaluation under microgravity, and astronaut-AI interaction patterns are all biology-medicine-AI hybrid questions. The bedside-bioprinting and iPSC infrastructure couples directly to Humanoid Robotics for autonomous medical manipulation in remote habitats.

Where to read further

ENERA treats the energy infrastructure that INTEGRITISSUE’s clinical architecture sits on. ARCANE treats the food and microbiome layer that INTEGRITISSUE feeds into. The AI Safety, Humanoid Robotics, and Agentic Systems research pillars treat the autonomous-control and clinical-decision substrate. The manifesto provides the broader architectural framing.